Generator Integrated System: Elution–Purification–Concentration Integration

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Generator Integrated System: Elution–Purification–Concentration Integration

Ethylenediaminetetraacetic acid) for detection of blood–brain barrier integrity and 68 Ga-PLED (PLED N, N’-bis(pyridoxyl)ethylenediamine-N, N’-diacetic acid) or 68Ga-EDTA for renal function investigation. 68Ga-based targeting PET radiopharmaceuticals under phase III clinical trial…

read more

Diversity of 68Ga-Based Imaging Agents

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Diversity of 68Ga-Based Imaging Agents

Fig. 1 Elution profile of a 68Ge/68Ga generator where one fraction was 1 mL (fraction 1 = 0.3 mL, fraction 7 = 0.7 mL) for total eluted volume of 6 mL. The profiles for 68Ga elution and 68Ge breakthrough are similar….

read more

for PET Imaging of Infection and Inflammation

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on for PET Imaging of Infection and Inflammation

Fig. 1 Biodistribution of Ga-citrate in normal rats. Ga-citrate (40 MBq) was injected into rats, and images were acquired at 60 min post-injection. 67Ga-citrate SPECT images are shown in a (before purification) and…

read more

Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign

Fig. 1 CT-guided core-needle biopsy of the mediastinal tumor showed a moderately differentiated cellular neoplasm with syncytial growth pattern lacking mitotic activity. Immunohistochemically the tumor was positive for EMA (Fig. 1) while…

read more

Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC

  DOTATATE DOTANOC DOTATOC Therapy cycles 185 9 59 83 male, 102 female 3 male, 6 female 35 male, 24 female 59.7 ± 10.6 years 64.4 ± 9.9 years 62.3 ± 10.0 years 27.5–79.7 years 47.9–77.5 years 41.2–81.7 years Activity per cycle…

read more
Get Clinical Tree app for offline access